Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23942042 | 0.84 | HSD17B10 (0.41) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL8285616 | 0.83 | HSD17B10 (0.37) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL5404302 | 0.83 | HSD17B10 (0.37) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL8288621 | 0.83 | HSD17B10 (0.37) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL27207278 | 0.81 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL27203890 | 0.81 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL35211488 | 0.80 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL21996480 | 0.79 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL883020 | 0.78 | HSD17B10 (0.38) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL29148977 | 0.78 | HSD17B10 (0.41) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149023-B2 | Substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-19 | — | — | US | disclosed |
| EP-3700898-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2020-09-02 | — | — | EP | disclosed |
| US-20200255402-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255402-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | GLS, TNNI3, CYP11B2 | HSD17B10 999/4885CHRM2 3734/4885CHRM1 3321/4885 |
| US-11149023-B2 | Substituted triazole derivatives and uses thereof | GLS, TNNI3, CYP11B2 | HSD17B10 999/4885CHRM2 3734/4885CHRM1 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.